ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Clinical trials for ER-POSITIVE, HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE, HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE, HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Blood test catches cancer early: new drug aims to stop spread
Disease control Recruiting nowThis Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 23, 2026 12:01 UTC
-
Can a chemo pill snuff out hidden breast cancer cells?
Disease control Recruiting nowThis study tests whether the chemotherapy drug capecitabine can eliminate tiny amounts of cancer DNA still present in the blood after standard treatment for early-stage ER+/HER2- breast cancer. About 15 patients whose blood tests positive for this 'molecular residual disease' wil…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New hope for advanced breast cancer: experimental drug targets resistant tumors
Disease control Recruiting nowThis early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects.…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
New hope for advanced breast cancer: umbrella trial tests multiple drug combos
Disease control Recruiting nowThis study is for people with advanced ER-positive breast cancer that has stopped responding to standard treatments. It tests several new drug combinations to see which ones work best and are safe. About 316 participants will be assigned to different treatment groups based on the…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
BREAST CANCER BREAKTHROUGH? new study lets patients choose chemo-free treatment
Disease control Recruiting nowThis study is for people with a common type of breast cancer (ER-positive, HER2-negative) that has a moderate to high risk of coming back based on tumor size and lymph node involvement, but a low genetic risk score. Instead of chemotherapy after surgery, participants can choose t…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 17, 2026 12:05 UTC